Payment overview · 2025
General Payments
$1,221.91
56 reported records · 19 companies
Healthcare provider profile · identity verified
Kae L Ferber, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Geriatric Medicine · NAPLES, FL · NPI 1255384749
Verified facts
What the public records show
CMS Open Payments records show Kae L Ferber, MD received $1,221.91 in general payments during 2025 across 56 reported records.
Amgen Inc. accounted for 21.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 30 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Otezla, Ozempic, Prolia, Rybelsus, Tymlos.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OTEZLA as an associated drug or biological on 177267 records involving 48600 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Otezla by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Prolia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Mounjaro by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Paxlovid by this doctor in 2024.
Radius Health, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Tymlos as an associated drug or biological on 17199 records involving 7328 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Tymlos by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $258.64 | 21.2% | 14 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $169.80 | 13.9% | 9 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $163.95 | 13.4% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $86.36 | 7.1% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $85.66 | 7.0% | 4 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $80.80 | 6.6% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $46.27 | 3.8% | 3 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $44.10 | 3.6% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $40.59 | 3.3% | 2 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $34.88 | 2.9% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $34.72 | 2.8% | 2 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $31.10 | 2.5% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $28.42 | 2.3% | 2 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$27.87 | 2.3% | 1 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $24.75 | 2.0% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $20.30 | 1.7% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $19.08 | 1.6% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $13.76 | 1.1% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $10.86 | 0.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,221.91 | 56 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $169.80 | 9 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $143.90 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $143.43 | 8 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $143.43 | 8 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $115.21 | 6 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $85.66 | 4 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $80.80 | 4 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $68.08 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $46.27 | 3 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $44.10 | 1 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $34.88 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $34.72 | 2 | 2025 |
Source payment records
|
|||||
| EVKEEZA Normalized: evkeeza |
Biological | Regeneron Healthcare Solutions, Inc. | $31.10 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $28.42 | 2 | 2025 |
Source payment records
|
|||||
| PROPEL Normalized: propel |
Device | Medtronic, Inc. | $27.87 | 1 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $24.75 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $22.36 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $22.36 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $22.36 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $20.30 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $20.05 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $20.05 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $19.08 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $19.08 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $18.28 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $18.23 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $18.23 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $16.64 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $13.76 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $10.86 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 52 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 33 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| OTEZLA otezla |
2025 | Otezla | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 81 | exact normalized | Medicare Part D |
| PROLIA prolia |
2025 | Prolia | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Tymlos tymlos |
2025 | Tymlos | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | OTEZLA open payments reported associated product |
CMS Open Payments — General Payments 177267 supporting records · 48600 recipient NPIs · example record 1226871616 |
Otezla · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
81 | 15 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
52 | 17 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
26 | 24 |
| Radius Health, Inc. Exact reporting entity; no affiliate inference |
2025 | Tymlos open payments reported associated product |
CMS Open Payments — General Payments 17199 supporting records · 7328 recipient NPIs · example record 1249501587 |
Tymlos · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 579 | 155 |
| Atorvastatin Calcium | Atorvastatin Calcium | 342 | 111 |
| Amlodipine Besylate | Amlodipine Besylate | 331 | 115 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 241 | 76 |
| Alprazolam | Alprazolam | 229 | 57 |
| Ezetimibe | Ezetimibe | 207 | 64 |
| Simvastatin | Simvastatin | 199 | 51 |
| Losartan Potassium | Losartan Potassium | 196 | 60 |
| Lisinopril | Lisinopril | 179 | 53 |
| Gabapentin | Gabapentin | 174 | 64 |
| Metoprolol Succinate | Metoprolol Succinate | 170 | 52 |
| Hydrochlorothiazide | Hydrochlorothiazide | 154 | 49 |
| Omeprazole | Omeprazole | 147 | 53 |
| Zolpidem Tartrate | Zolpidem Tartrate | 139 | 36 |
| Liothyronine Sodium | Liothyronine Sodium | 138 | 41 |
| Pravastatin Sodium | Pravastatin Sodium | 126 | 37 |
| Tramadol Hcl | Tramadol Hcl | 121 | 23 |
| Synthroid | Levothyroxine Sodium | 116 | 31 |
| Trazodone Hcl | Trazodone Hcl | 113 | 39 |
| Pantoprazole Sodium | Pantoprazole Sodium | 112 | 37 |
| Lorazepam | Lorazepam | 111 | 25 |
| Metformin Hcl | Metformin Hcl | 110 | 30 |
| Montelukast Sodium | Montelukast Sodium | 107 | 34 |
| Allopurinol | Allopurinol | 104 | 36 |
| Sertraline Hcl | Sertraline Hcl | 97 | 24 |
| Azithromycin | Azithromycin | 93 | 60 |
| Escitalopram Oxalate | Escitalopram Oxalate | 84 | 27 |
| Metoprolol Tartrate | Metoprolol Tartrate | 84 | 23 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 83 | 34 |
| Ozempic | Semaglutide | 81 | 15 |
| Meloxicam | Meloxicam | 79 | 29 |
| Methylprednisolone | Methylprednisolone | 79 | 59 |
| Carvedilol | Carvedilol | 76 | 25 |
| Famotidine | Famotidine | 74 | 27 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 72 | 29 |
| Atenolol | Atenolol | 72 | 19 |
| Duloxetine Hcl | Duloxetine Hcl | 68 | 25 |
| Finasteride | Finasteride | 67 | 21 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 66 | 35 |
| Potassium Chloride | Potassium Chloride | 65 | 17 |
| Fluticasone Propionate | Fluticasone Propionate | 61 | 30 |
| Furosemide | Furosemide | 58 | 17 |
| Spironolactone | Spironolactone | 57 | 23 |
| Clonazepam | Clonazepam | 55 | 12 |
| Eliquis | Apixaban | 52 | 17 |
| Prednisone | Prednisone | 52 | 16 |
| Valacyclovir | Valacyclovir Hcl | 52 | 28 |
| Tamsulosin Hcl | Tamsulosin Hcl | 51 | 19 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 50 | 13 |
| Diazepam | Diazepam | 48 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 47 | 14 |
| Estradiol | Estradiol | 46 | 24 |
| Pregabalin | Pregabalin | 45 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 41 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 41 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 41 | 25 |
| Clopidogrel | Clopidogrel Bisulfate | 40 | 11 |
| Amoxicillin | Amoxicillin | 39 | 32 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 39 | 13 |
| Cefuroxime | Cefuroxime Axetil | 37 | 27 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 37 | 13 |
| Cefdinir | Cefdinir | 36 | 30 |
| Celecoxib | Celecoxib | 36 | 16 |
| Glimepiride | Glimepiride | 36 | 14 |
| Torsemide | Torsemide | 35 | 11 |
| Ipratropium Bromide | Ipratropium Bromide | 34 | 20 |
| Nystatin | Nystatin | 34 | 14 |
| Clobetasol Propionate | Clobetasol Propionate | 33 | 17 |
| Jardiance | Empagliflozin | 33 | suppressed |
| Cephalexin | Cephalexin | 32 | 23 |
| Paroxetine Hcl | Paroxetine Hcl | 31 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 30 | suppressed |
| Estradiol (Twice Weekly) | Estradiol | 30 | suppressed |
| Lovastatin | Lovastatin | 30 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 29 | suppressed |
| Progesterone | Progesterone, Micronized | 29 | 12 |
| Metformin Hcl Er | Metformin Hcl | 28 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 28 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 28 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 27 | suppressed |
| Bupropion Xl | Bupropion Hcl | 27 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 27 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 27 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 26 | 24 |
| Propranolol Hcl | Propranolol Hcl | 26 | suppressed |
| Xarelto | Rivaroxaban | 26 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 25 | suppressed |
| Temazepam | Temazepam | 25 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 25 | suppressed |
| Memantine Hcl | Memantine Hcl | 24 | suppressed |
| Eszopiclone | Eszopiclone | 22 | suppressed |
| Glipizide | Glipizide | 22 | suppressed |
| Ibuprofen | Ibuprofen | 22 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 22 | 14 |
| Acyclovir | Acyclovir | 21 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 21 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 21 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 21 | suppressed |
| Mirtazapine | Mirtazapine | 20 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 19 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 19 | 15 |
| Tolterodine Tartrate | Tolterodine Tartrate | 19 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 18 | suppressed |
| Estradiol (Once Weekly) | Estradiol | 18 | suppressed |
| Klor-Con 10 | Potassium Chloride | 18 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 18 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 17 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 17 | suppressed |
| Mupirocin | Mupirocin | 17 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 17 | suppressed |
| Valsartan | Valsartan | 17 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 16 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 16 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 16 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 15 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 15 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 15 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 15 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 15 | suppressed |
| Lidocaine | Lidocaine | 15 | suppressed |
| Repatha Sureclick | Evolocumab | 15 | suppressed |
| Testosterone | Testosterone | 15 | suppressed |
| Chlorthalidone | Chlorthalidone | 14 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 14 | suppressed |
| Fenofibrate | Fenofibrate | 14 | suppressed |
| Januvia | Sitagliptin Phosphate | 14 | suppressed |
| Levetiracetam | Levetiracetam | 14 | suppressed |
| Mounjaro | Tirzepatide | 14 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 14 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 14 | suppressed |
| Telmisartan | Telmisartan | 14 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 14 | suppressed |
| Aripiprazole | Aripiprazole | 13 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 13 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 13 | suppressed |
| Entresto | Sacubitril/Valsartan | 13 | suppressed |
| Fluconazole | Fluconazole | 13 | suppressed |
| Prolia | Denosumab | 13 | suppressed |
| Verapamil Er | Verapamil Hcl | 13 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Hydrocortisone | Hydrocortisone | 12 | suppressed |
| Levofloxacin | Levofloxacin | 12 | 12 |
| Methylphenidate Hcl | Methylphenidate Hcl | 12 | suppressed |
| Rybelsus | Semaglutide | 12 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 12 | suppressed |
| Tymlos | Abaloparatide | 12 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 12 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 11 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 11 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 11 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 11 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 11 | suppressed |
| Ondansetron Odt | Ondansetron | 11 | suppressed |
| Otezla | Apremilast | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,221.91 · 56 records | Amgen Inc. | ABRYSVO, CAPVAXIVE, COMIRNATY, Cologuard Collection Kit, ELIQUIS, EVENITY, EVKEEZA, FARXIGA, FREESTYLE LIBRE 3, GARDASIL 9, INSPIRE, JARDIANCE, KISUNLA, Korlym, LEQVIO, Leqembi, NEXLETOL, NURTEC ODT, OTEZLA, Ozempic, PREVNAR 20, PROLIA, PROPEL, REPATHA, Rybelsus, The Cologuard Plus Collection Kit, Tymlos, VOQUEZNA, Wegovy, ZORYVE | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error